These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6992238)

  • 1. Human plasma transforms prostacyclin (PGI2) into a platelet antiaggregatory substance which contracts isolated bovine coronary arteries.
    Gimeno MF; Sterin-Borda L; Borda ES; Lazzari MA; Gimeno AL
    Prostaglandins; 1980 Jun; 19(6):907-16. PubMed ID: 6992238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human platelet rich plasma and human serum protects from inactivation the antiaggregatory capacity of prostacyclin-like material (PGI2) produced by the rat stomach fundus.
    Borda ES; Lazzari MA; Gimeno MF; Gimeno AL
    Prostaglandins; 1980 Jun; 19(6):899-905. PubMed ID: 6992237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-keto PGE1: a possible metabolite of prostacyclin having platelet antiaggregatory effects.
    Quilley CP; McGiff JC; Lee WH; Sun FF; Wong PY
    Hypertension; 1980; 2(4):524-8. PubMed ID: 6995292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of prostacyclin (PGI2) on tissues which detect prostaglandins (PG'S).
    Omini C; Moncada S; Vane JR
    Prostaglandins; 1977 Oct; 14(4):625-32. PubMed ID: 339280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation.
    Aiken JW; Gorman RR; Shebuski RJ
    Prostaglandins; 1979 Apr; 17(4):483-94. PubMed ID: 111306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. dl-9a-Deoxy-9a-methylene-PGI2 (a stable prostacyclin derivative): preliminary pharmacological data.
    Ceserani R; Grossoni M; Longiave D; Mizzotti B; Pozzi O; Dembinska-Kiec A; Bianco S
    Prostaglandins Med; 1980 Aug; 5(2):131-9. PubMed ID: 6251496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The release of prostacyclin (PGI2) by pentoxifylline from human vascular tissue.
    Matzky R; Darius H; Schrör K
    Arzneimittelforschung; 1982; 32(10):1315-8. PubMed ID: 6817760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological profile of a bioactive aortic substance (BAS), released by vessel rings from indomethacin-treated rats.
    Chaud MA; Shattner M; González ET; Lazzari MA; Gimeno MF; Gimeno AL
    Prostaglandins Leukot Med; 1986 May; 22(2):211-20. PubMed ID: 3523541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostacyclin (PGI2) mediates hypoxic relaxation of bovine coronary arterial strips.
    Roberts AM; Messina EJ; Kaley G
    Prostaglandins; 1981 Apr; 21(4):555-69. PubMed ID: 7019974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of prostacyclin on platelet-activating factor induced rabbit and platelet aggregation.
    Bussolino F; Camussi G
    Prostaglandins; 1980 Nov; 20(5):781-91. PubMed ID: 6258196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV; Aiken JW; Shebuski RJ; Gorman RR
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The action of non-steroidal antiinflammatory agents on platelet aggregation and vessel tone in relation to inhibition of PGI2- and thromboxane-release. With particular reference to 5-benzoyl-alpha-methyl-2-thiophene acetic acid (tiaprofenic acid).
    Kuhn A; Sauerland S; Schiffer K; Schrör K
    Arzneimittelforschung; 1980; 30(9):1538-42. PubMed ID: 7006618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular relaxing activity and stability studies of 10,10-difluoro-13,14-dehydroprostacyclin.
    Hatano Y; Kohli JD; Goldberg LI; Fried J; Mehrotra MM
    Proc Natl Acad Sci U S A; 1980 Nov; 77(11):6846-50. PubMed ID: 7005902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mode of action of coronary arterial relaxation by prostacyclin.
    Holzmann S; Kukovetz WR; Schmidt K
    J Cyclic Nucleotide Res; 1980; 6(6):451-60. PubMed ID: 6163806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
    Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
    Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet prostacyclin binding in smokers.
    Jaschonek K; Weisenberger H; Tidow S; Daiss W; Renn W; Ostendorf P
    J Lab Clin Med; 1986 Aug; 108(2):88-95. PubMed ID: 3016128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsomal preparations of normal bovine iris-ciliary body generate prostacyclin-like but not thromboxane-A2-activity.
    Kulkarni FS; Eakins HM; Saber WL; Eakins KE
    Prostaglandins; 1977 Oct; 14(4):689-700. PubMed ID: 339281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of prostacyclin, 6-keto-PGF1 alpha PGF2 alpha and 15[S]15-methyl-PGF2 alpha on platelet aggregation in vitro.
    Marmo E; Somma A; Ottavo R; Vairo G; Spaziante G; DiMezza F; Paone G
    J Med; 1981; 12(2-3):97-108. PubMed ID: 7024451
    [No Abstract]   [Full Text] [Related]  

  • 19. (5Z)-carbacyclin displays agonist-antagonist properties on prostacyclin-receptors in platelets and vascular myocytes.
    Corsini A; Oliva D; Folco GC; Giovanazzi S; Noe' MA; Fumagalli R; Nicosia S
    Biomed Biochim Acta; 1988; 47(10-11):S104-7. PubMed ID: 3073757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses of isolated feline and human cerebral arteries to prostacyclin and some of its metabolites.
    Uski T; Andersson KE; Brandt L; Edvinsson L; Ljunggren B
    J Cereb Blood Flow Metab; 1983 Jun; 3(2):238-45. PubMed ID: 6341384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.